C. U. Afsar Et Al. , "Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma," JOURNAL OF INFECTION AND CHEMOTHERAPY , vol.23, pp.196-200, 2017
Afsar, C. U. Et Al. 2017. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma. JOURNAL OF INFECTION AND CHEMOTHERAPY , vol.23 , 196-200.
Afsar, C. U., Karabulut, M., Karabulut, S., Alis, H., Gonenc, M., Dagoglu, N., ... Serilmez, M.(2017). Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma. JOURNAL OF INFECTION AND CHEMOTHERAPY , vol.23, 196-200.
Afsar, Cıgdem Et Al. "Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma," JOURNAL OF INFECTION AND CHEMOTHERAPY , vol.23, 196-200, 2017
Afsar, Cıgdem U. Et Al. "Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma." JOURNAL OF INFECTION AND CHEMOTHERAPY , vol.23, pp.196-200, 2017
Afsar, C. U. Et Al. (2017) . "Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma." JOURNAL OF INFECTION AND CHEMOTHERAPY , vol.23, pp.196-200.
@article{article, author={Cıgdem Usul Afsar Et Al. }, title={Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma}, journal={JOURNAL OF INFECTION AND CHEMOTHERAPY}, year=2017, pages={196-200} }